Summary
Cardiac β-adrenoceptor density and β1- and β2-subtype distribution were examined in human left ventricular myocardium from transplant donors serving as controls and from patients with mitral valve stenosis, aortic valve stenosis, idiopathic dilated cardiomyopathy, and ischaemic cardiomyopathy respectively. The total β-adrenoceptor density was similar in transplant donors and patients with moderate heart failure (NYHA II–III) due to mitral valve stenosis, but was markedly reduced in all forms of severe heart failure (NYHA III–IV) studied. A reduction of both β1- and β2-adrenoceptors was found in patients with severe heart failure due to mitral valve stenosis or ischaemic cardiomyopathy. In contrast, a selective down-regulation of β1-adrenoceptors with unchanged β2-adrenoceptors and hence a relative increase in the latter was observed in idiopathic dilated cardiomyopathy and aortic valve stenosis. It is concluded that the extent of total β-adrenoceptor down-regulation is related to the degree of heart failure. Selective loss of β1-adrenoceptors is not specific for idiopathic dilated cardiomyopathy but also occurs in aortic valve stenosis. Changes in β1- and β2-subtype distribution are rather related to the aetiology than to the clinical degree of heart failure.
This is a preview of subscription content, log in via an institution to check access.
References
Böhm M, Pieske B, Schnabel P, Schwinger R, Kemkes B, Klövekorn WP, Erdmann E (1989) Reduced effects of dopexamine on force of contraction in the failing human heart despite preserved β2-adrenoceptor subpopulation. J Cardiovasc Pharmacol 14:549–559
Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB (1982) Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med 307:205–211
Bristow MR, Kantrowitz NE, Ginsburg R, Fowler MB (1985) Betaadrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol 17 (suppl 2):41–52
Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S, Stinson EB (1986) β1- and β2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective β1-receptor down-regulation in heart failure. Circ Res 59:297–309
Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, Cates AE, Feldman AM (1990) β-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 82 (suppl 1):I-12-I-25
Brodde OE (1987) Cardiac beta-adrenergic receptors. ISI Atlas Sci Pharmacol 1:107–112
Brodde OE, Schüler S, Kretsch R, Brinkmann M, Borst HG, Hetzer R, Reidemeister JC, Warnecke H, Zerkowski HR (1986) Regional distribution of β-adrenoceptors in the human heart: coexistence of functional β1- and β2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy. J Cardiovasc Pharmacol 8:1235–1242
Brodde OE, Zerkowski HR, Borst HG, Maier W, Michel MC (1989a) Drug- and disease-induced changes of human cardiac β1- and β2-adrenoceptors. Eur Heart J 10 (suppl B):38–44
Brodde OE, Zerkowski HR, Doetsch N, Motomura S, Khamssi M, Michel MC (1989b) Myocardial beta-adrenoceptor changes in heart failure: concomitant reduction in beta1- and beta2 adrenoceptor function related to the degree of heart failure in patients with mitral valve disease. J Am Coll Cardiol 14:323–331
Buxton BF, Jones CR, Molenaar P, Summers RJ (1987) Characterization and autoradiographic localization of β-adrenoceptor subtypes in human cardiac tissues. Br J Pharmacol 92:299–310
Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector R (1984) Plasma norepinephrine as guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819–823
Danielsen W, Leyen HVD, Meyer W, Neumann J, Schmitz W, Scholz H, Starbatty J, Stein B, Döring V, Kalmar P (1989) Basal and isoprenaline-stimulated cAMP content in failing versus nonfailing human cardiac preparations. J Cardiovasc Pharmacol 14:171–174
Dooley DJ, Bittiger H, Reymann NC (1986) CGP 20712 A: a useful tool for quantitating β1- and β2-adrenoceptors. Eur J Pharmacol 130:137–139
Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR (1986) Assessment of the β-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation 74:1290–1302
Francis GS (1985) Neurohumoral mechanism involved in congestive heart failure. Am J Cardiol 55:15A–21A
Francis GS, Cohn JN (1986) The autonomic nervous system in congestive heart failure. Ann Rev Med 37:235–247
Kaumann AJ, Lemoine H (1987) β2-adrenoceptor-mediated positive inotropic effect of adrenaline in human ventricular myocardium. Naunyn-Schmiedeberg's Arch Pharmacol 335:403–411
Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG (1967) Differentiation of receptor systems activated by sympathomimetic amines. Nature 214:597–598
Lemoine H, Schönell H, Kaumann AJ (1988) Contribution of β1-and β-adrenoceptors of human atrium and ventricle to the effects of noradrenaline and adrenaline as assessed with (−)-atenolol. Br J Pharmacol 95:55–66
Michel MC, Maisel AS, Brodde OE (1990) Mitigation of β1-and or β2-adrenoceptor function in human heart failure. Br J Clin Pharmacol 30 [suppl 1]:37S–42S
Molenaar P, Summers RJ (1987) Characterization of beta1- and beta2-adrenoceptors in guinea pig atrium: functional and receptor binding studies. J Pharmacol Exp Ther 241:1041–1047
Scatchard G (1949) The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51:660–672
Schmitz W, Scholz H, Erdmann E (1987) Effects of α- and β-adrenergic agonists, phosphodiesterase inhibitors and adenosine on isolated human heart muscle preparations. Trends Pharmacol Sci 8:447–450
Author information
Authors and Affiliations
Additional information
Send offprint requests to M. Steinfath at the above address
Rights and permissions
About this article
Cite this article
Steinfath, M., Geertz, B., Schmitz, W. et al. Distinct down-regulation of cardiac β1- and β2-adrenoceptors in different human heart diseases. Naunyn-Schmiedeberg's Arch Pharmacol 343, 217–220 (1991). https://doi.org/10.1007/BF00168613
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00168613